

**AMENDMENTS TO THE CLAIMS**


Please cancel Claims 1-8 without prejudice and insert therefore new Claims 9-16. This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**


Claims 1-8 (canceled)

9. (new) A method for the treatment of neurodegeneration which comprises administering to a patient in need of such treatment a glycine/NMDA antagonist and a tachykinin NK-1 receptor antagonist.

10. (new) The method of Claim 9 wherein the glycine/NMDA antagonist is:



or



11. (new) The method of Claim 10 wherein the glycine/NMDA antagonist is UK-240,455.

12. (new) The method of Claim 10 wherein the glycine/NMDA antagonist is UK-333,747.

13. (new) The method of Claim 9 wherein the tachykinin NK-1 receptor antagonist is aprepitant.

14. (new) The method of Claim 9 wherein the neurodegeneration results from stroke.

15. (new) The method of Claim 9 wherein the neurodegeneration results from cerebral ischemia.

16. (new) A pharmaceutical composition which comprises a glycine/NMDA antagonist, a tachykinin NK-1 receptor antagonist and a pharmaceutically acceptable carrier.